Chula Vista, CA, United States of America

Marlon Carlos

This inventor holds 23 USPTO granted patents and 6 published patent applications, plus 1 CIPO patent and 3 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Arena Pharmaceuticals, Inc., Acadia Pharmaceuticals Inc., Other. Active years: 2008-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Marlon Carlos. Retrieved from https://idiyas.com/inventor/marlon-carlos

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 23 (Patent Applications = 6)

% Patents Active = 87.0

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 3 (Patent Applications = 5)

Average Co-Inventor Count = 6.7

ph-index = 7

Forward Citations = 124(Granted Patents)

Location History:

Santee, CA (US) (2008)
Glendale, AZ (US) (2023)
Chula Vista, CA (US) (2012 - 2024)

Company Filing History:

16 out of 218

Arena Pharmaceuticals, Inc.

patents

6 out of 94

Acadia Pharmaceuticals Inc.

patents

1 out of 834,513

Other

patents

Years Active: 2008-2025

Loading Chart...

Areas of Expertise:

Trofinetide

L-Arginine Salt

SIPI Receptor

5-HT2A Modulator

Crystalline Forms

N-Methylpiperidin-4-yl

Pyrazolo[3,4-d]pyrimidine

Preparation Methods

Pharmaceutical Composition

Urea Derivatives

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12492167 - Crystalline forms of trofinetide (2025-12-09),

2. 12378198 - Crystalline l-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(compound1) for use in SIPI receptor-associated disorders (2025-08-05),

3. 11884626 - Crystalline L-arginine salt of ()-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compound1) for use in S1Preceptor-associated disorders (2024-01-30),

4. 11840515 - Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c (2023-12-12),

5. 11827600 - Crystalline forms of trofinetide (2023-11-28),

6. 11091435 - Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3, 4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(compound1) for use in S1Preceptor-associated disorders (2021-08-17),

7. 10981871 - Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form C (2021-04-20),

8. 10981870 - Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form (2021-04-20),

9. 10676435 - Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compound 1) for use in SIPI receptor-associated disorders (2020-06-09),

10. 10597363 - Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form C (2020-03-24),

11. 10583122 - Composition of a 5-HT2A serotonin receptor modulator useful for the treatment of disorders related thereto (2020-03-10),

12. 10543193 - Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto (2020-01-28),

13. 10301262 - Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compund1) for use in SIPI receptor-associated disorders (2019-05-28),

14. 10117851 - Composition of a 5-HT2A serotonin receptor modulator useful for the treatment of disorders related thereto (2018-11-06),

15. 10071075 - Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto (2018-09-11),

Title: Marlon Carlos: A Trailblazer in Pharmaceutical Innovations

Introduction

Marlon Carlos, an inventor based in Chula Vista, California, has made significant contributions to the field of pharmaceuticals. With a remarkable portfolio of 21 patents, Carlos's work focuses on developing innovative treatments for various medical conditions, particularly those associated with S1Preceptor disorders.

Latest Patents

Among his latest patents is a groundbreaking invention involving a crystalline L-arginine salt of ()-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid (Compound 1). This invention provides a novel crystalline free-plate habit for the treatment of S1Preceptor-associated disorders, which include significant diseases such as cancer, autoimmune diseases, and conditions related to vascular integrity. Furthermore, Carlos has disclosed methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (pimavanserin) and its tartrate salt, showcasing his expertise in complex chemical synthesis.

Career Highlights

Throughout his career, Marlon Carlos has worked with leading pharmaceutical companies, including Arena Pharmaceuticals, Inc. and Acadia Pharmaceuticals Inc. His innovative spirit and dedication to improving medical treatments culminate in his extensive patent portfolio and ongoing research efforts.

Collaborations

Working alongside notable colleagues such as Lee Alani Selvey and You-An Ma, Carlos has been part of a collaborative environment that fosters creativity and scientific advancement. This teamwork has undoubtedly contributed to the successful development of his groundbreaking inventions.

Conclusion

Marlon Carlos stands out as a prominent inventor in the pharmaceutical industry, with a strong patent portfolio and innovative research focused on improving treatment options for critical health issues. His contributions will likely continue to influence the field for years to come.

Profile summary based on public USPTO records.